Understanding COVID-19 in patients with blood cancers
Epidemiology of COVID-19 Infection in Patients With Hematological Malignancies: A European Haematology Association Survey
This study looks at how COVID-19 affects people with blood cancers in different European countries to see how often it happens and what the outcomes are.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne Academic / other |
| Locations | 6 sites (Brescia and 5 other locations) |
| Trial ID | NCT04733729 on ClinicalTrials.gov |
What this trial studies
This project aims to investigate the epidemiology of COVID-19 among patients with hematological malignancies across various European countries. It will involve a multicenter, international observational study that includes both retrospective and prospective data collection on COVID-19 cases in these patients. The study will assess the incidence, outcomes, and mortality rates associated with COVID-19 in individuals with hematological malignancies, providing valuable insights for tailored patient management. Clinical follow-up will be conducted to monitor survival rates and other relevant outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a history of hematological malignancies who have tested positive for SARS-CoV-2.
Not a fit: Patients with hematological diseases other than malignancies or those who have not tested positive for SARS-CoV-2 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of COVID-19 impacts on patients with blood cancers, leading to improved treatment and management strategies.
How similar studies have performed: While there is limited data on COVID-19 in hematological malignancies, this study aims to fill a significant knowledge gap, making it a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age equal to or greater than 18 years of age. * History of hematological malignancies (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status. * Active hematological malignancies at any stage/status. * Diagnosis of hematological malignancy (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status. * SARS-CoV-2 positive test (nasopharyngeal, BAL, fecal), documented by Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panels. Exclusion Criteria: * Hematological diseases, other than hematological malignancies. * Not tested positive for SARS-CoV-2 * Patients "off therapy" for more than 5 years
Where this trial is running
Brescia and 5 other locations
- ASST-Spedali Civili — Brescia, Italy (Recruiting)
- AOU Policlinico Federico II — Naples, Italy (Recruiting)
- Fondazione Policlinico A. Gemelli IRCCS — Rome, Italy (Recruiting)
- Istituto Nazionale Tumori Regina Elena IFO — Rome, Italy (Recruiting)
- Osp. di Circolo-Fondazione Macchi — Varese, Italy (Recruiting)
- AOUI Verona — Verona, Italy (Recruiting)
Study contacts
- Study coordinator: livio pagano, Prof
- Email: livio.pagano@unicatt.it
- Phone: +390630154180
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.